Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.

ABSTRACT:

Background

KRAS mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in.

Kras

mutated patients is not clear.

Methods

Eligible patients diagnosed with NSCLC and found to have a KRAS mutation were identified in an institutional lung cancer database. Demographic, clinical, and molecular data was collected and analyzed.

Results

A total of 60 patients were identified for this retrospective analysis. Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had

SUBMITTER: Amanam I 

PROVIDER: S-EPMC7578487 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature